nach oben

Neuroradiology

Erschienen in:

01.12.2011 | Functional Neuroradiology

F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study

verfasst von: Amburanjan Santra, Rakesh Kumar, Punit Sharma, Chandrashekhar Bal, Pramod Kumar Julka, Arun Malhotra

Erschienen in: Neuroradiology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Recurrent gliomas are usually histologically high grade; either due to recurrence of a de novo high-grade primary or anaplastic transformation in case of low-grade tumors. Survival in these patients is variable. The objective of the present study is to evaluate the role of FDG PET-CT for predicting survival in a large group of patients with suspected recurrent glioma.

Methods

A total of 81 previously treated histopathologically proven glioma patients; with clinical and conventional imaging findings suspicious of recurrence were included in this study. All patients underwent FDG PET-CT study. Based on tumor to white matter (T/W) and tumor to grey matter (T/G) ratios, all lesions were scored on PET-CT (PET scores 0, 1 and 2). Patients were followed up clinically and by repeated imaging. Data was censored, if the patient died of disease or at the end of the study. Survival analysis was done for each variable employing univariate analysis followed by multivariate analysis, using variables found significant on univariate analysis.

Results

PET score was found to be the most significant predictor of survival in univariate and multivariate analysis (p 0.003). Patients having PET score 2 had poorer survival compared to both PET score 0 (p 0.001) and PET score 1 (p 0.004). Other covariates found to have significant correlation with survival were primary treatment modality and clinical symptoms at the time of recurrence.

Conclusion

FDG uptake on PET-CT is a strong predictor of survival in patients with suspected recurrent glioma.

Levin VA, Leibel SA, Gutin PH (1997) Management of central nervous system neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles & Practice of Oncology. Lippincott-Raven Publishers, Philadelphia, pp 2022–2082

Kleihurs P, Cavenee WK (eds) (2000) World Health Organization Classification of Tumors: pathology and genetics of tumors of the nervous system. Oxford University Press, New York

Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncology 1:44–51

Jung V, Romeike BFM, Henn W, Feiden W, Moringlane JRM, Zang KD et al (1999) Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58:993–999PubMedCrossRef

Central Brain Tumor Registry of the United States: 2005–2006. Available at http://www.cbtrus.org

Bampoe JO, Bauman G, Cairncross JG (1999) Adult low-grade gliomas: natural history, prognostic factors, and timing of treatment. In: Rock JP, Rosenblum ML, Shaw EG, Cairncross JG (eds) The practical management of low-grade primary brain tumors. Lippincott Williams & Wilkins, Philadelphia, pp 135–148

Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP et al (1996) Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38:872–879PubMedCrossRef

McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31:636–642PubMedCrossRef

Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M et al (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183–188PubMedCrossRef

10.

Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B et al (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923–929PubMedCrossRef

11.

Ricci PE (1999) Imaging of adult brain tumors. Neuroimag Clin N Am 9:651–669

12.

Goldman S, Wikler D, Damhaut P, Monclus M, Levivier M, Pirotte B et al (1997) Positron emission tomography and brain tumours. Acta Neurol Belg 97:183–186PubMed

13.

Mirzaei S, Knoll P, Kohn H (2001) Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. N Engl J Med 344:2030–2031PubMedCrossRef

14.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P et al (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography guided stereotactic biopsy. Cancer 78:1098–1106PubMedCrossRef

15.

Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861–1867PubMed

16.

Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197PubMedCrossRef

17.

Di CG, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ et al (1988) Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 150:189–197

18.

Brock CS, Young H, O’Reilly SM, Matthews J, Osman S, Evans H et al (2000) Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82:608–615PubMedCrossRef

19.

Roelcke U, von Ammon K, Hausmann O, Kaech DL, Vanloffeld W, Landolt H et al (1999) Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy. J Neurol Neurosurg Psychiatr 66:644–647PubMedCrossRef

20.

Herholz K, Holzer T, Bauer B, Schröder R, Voges J, Ernestus RI et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322PubMed

21.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A et al (2004) Comparison of 18F-FDG and 11C methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293–1298PubMed

22.

De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D Jr et al (1996) Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39:470–477PubMed

23.

Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W et al (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62:1074–1078PubMedCrossRef

24.

Levin VA, Prados MD (1992) Treatment of recurrent gliomas and, metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10:766–771PubMed

25.

Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19:69–74PubMedCrossRef

26.

Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH et al (1982) Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329PubMed

27.

Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S (1993) Glucose consumption in recurrent gliomas. Neurosurgery 33:28–33PubMedCrossRef

28.

Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK (1993) Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33:540–548PubMedCrossRef

29.

Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M et al (1994) Diagnosis of recurrent brain tumor: value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 163:1459–1465PubMed

30.

Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R et al (1985) Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62:816–822PubMedCrossRef

31.

DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123PubMedCrossRef

32.

Berg G, Blomquist E, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 42:582–588PubMedCrossRef

33.

Barker FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–720PubMedCrossRef

34.

Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776–783PubMedCrossRef

35.

Wolfe RA, Strawderman RL (1996) Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 27:124–129PubMedCrossRef

36.

Glesby MJ, Hoover DR (1996) Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 124:999–1005PubMed

37.

Barker FG II (1996) Analysis of the relationship between long-term operative success and a transient or delayed operative side effect. Neurosurgery 39:412–416PubMedCrossRef

Titel: F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study
verfasst von: Amburanjan Santra
Rakesh Kumar
Punit Sharma
Chandrashekhar Bal
Pramod Kumar Julka
Arun Malhotra
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Neuroradiology / Ausgabe 12/2011
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-011-0898-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt–Jakob disease: correlation with clinical course

European Society of Neuroradiology

Frontiers of stent-assisted aneurysm coiling

Endolympathic hydrops in patients with vestibular schwannoma: visualization by non-contrast-enhanced 3D FLAIR

Detailed imaging of the normal anatomy and pathologic conditions of the cavernous region at 3 Tesla using a contrast-enhanced MR angiography